The impact of touch during digital communications.
Agios’ oral drug secures PhIII success in transfusion-independent thalassemia patients
Agios Pharmaceuticals’ oral drug candidate is a step closer to market after it succeeded in a late-stage study in thalassemia patients who don’t need regular